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Abstract
Objective Endometrial carcinoma (EC) is the sixth most common cancer
in women and therapies are limited for advanced and recurrent disease.
Patient-derived tumor xenograft (PDTX) models are becoming popular tools in
translational research because of their histological and genetic similarity to the
original tumors and the ability to predict therapeutic response to treatments. Here,
we established and characterized a panel of 24 EC PDTX models which includes
the major histological and genetic subtypes observed in patients. Methods Fresh
tumor tissues collected from primary, metastatic and recurrent type I and type II
EC patients were engrafted in immunocompromised mice. Histology, vimentin,
and cytokeratin expression were evaluated, together with Microsatellite instability
(MSI), mutation profiling by Whole Exome Sequencing and copy number profiling
by Whole Genome Low Coverage Sequencing. The efficacy of both PI3K and
MEK inhibitors was evaluated in a model of endometrioid carcinoma h...
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H I G H L I G H T S
• Patient-derived tumor xenografts
(PDTXs) can be established from
endometrial cancer.
• Endometrial cancer PDTXs maintain the
general features of the human tumor.
• Such models can be used as preclinical
tools to study therapy response.
G R A P H I C A L A B S T R A C T
General overviewof the establishment of endometrial PDTXmodels. Primary tumor tissue (F0)was surgically re-
moved and implanted in mice. In parallel, remaining tissue was fresh-frozen and formalin-ﬁxed for histological
and genetic analysis. After engraftment (F1), tumor tissue was implanted in new mice for expansion (F2). Tu-
mors were further transplanted in F3 generation for histological and genetic validation and compared with the
primary tumor.
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Objective. Endometrial carcinoma (EC) is the sixth most common cancer in women and therapies are
limited for advanced and recurrent disease. Patient-derived tumor xenograft (PDTX) models are becoming
popular tools in translational research because of their histological and genetic similarity to the original
tumors and the ability to predict therapeutic response to treatments. Here, we established and character-
ized a panel of 24 EC PDTX models which includes the major histological and genetic subtypes observed
in patients.
Methods. Fresh tumor tissues collected from primary, metastatic and recurrent type I and type II EC pa-
tients were engrafted in immunocompromised mice. Histology, vimentin, and cytokeratin expression were
evaluated, together with Microsatellite instability (MSI), mutation proﬁling by Whole Exome Sequencing
and copy number proﬁling by Whole Genome Low Coverage Sequencing. The efﬁcacy of both PI3K and
MEK inhibitors was evaluated in a model of endometrioid carcinoma harboring PTEN, PIK3CA and KRAS
mutations.
Results.We observed good similarity between primary tumors and the corresponding xenografts, at his-
tological and genetic level. Among the engrafted endometrioid models, we found a signiﬁcant enrichment
of MSI and POLE mutated tumors, compared to non-engrafted samples. Combination treatment with NVP-
BEZ235 and AZD6244 showed the possibility to stabilize the tumor growth in one model originated from
a patient who already received several lines of chemotherapy.
Conclusion. The established EC PDTX models, resembling the original human tumors, promise to be use-
ful for preclinical evaluation of novel combination and targeted therapies in speciﬁc EC subgroups.
© 2015 Elsevier Inc. All rights reserved.
1. Introduction
Endometrial carcinoma (EC) is the most common gynecological
malignancy in the Western World, and the number of new cases is
expected to rise in the next 10 years [1]. ECs are traditionally classi-
ﬁed into two main groups. Type I ECs, with endometrioid histology,
represent 80% of the cases and count for 15–20% of recurrences. In
contrast, type II tumors, consisting of serous or clear cell histology,
are less common but account for more than 50% of recurrences [2].
Since treatment options for advanced, metastatic and recurrent dis-
ease are currently limited in efﬁcacy, there is an urgent need for clin-
ical implementation of novel therapeutic strategies.
The recent comprehensive molecular characterization from TCGA
revealed that, based on integrated genomic analysis, ECs can be
Table 1
Overview of patient characteristics and engrafted patient-derived tumor xenograft models of endometrial cancer.
ID PDTX
model
Histology Primary/recurrence Grade FIGO Before engraftment After engraftment Survival since
diagnosis
(months)
Time
F0–F1
(months)
Treatment Response Treatment Response
PDTX-EMC028 Endometrioid Primary 1 I No NA No NA N24 9
PDTX-EMC032 Endometrioid Primary 1 I No NA No NA 12–24 8
PDTX-EMC044 Endometrioid Primary 1 I No NA Doc-Cyclo Yes 12–24 3
PDTX-EMC015 Endometrioid Primary 1 III T-C partial No NA NA 3
PDTX-EMC001 Endometrioid Primary 2 IV No NA P-C Yes NA 5
PDTX-EMC034 Endometrioid Recurrence
(vagina)
2 NA No NA No NA N24 4
PDTX-EMC016 Endometrioid Primary 2 I No NA No NA N24 1.5
PDTX-EMC049 Endometrioid Primary 2 I No NA No NA 12–24 4.5
PDTX-EMC040 Endometrioid Primary 3 I No NA T-C Yes 12–24 7
PDTX-EMC046 Endometrioid Primary 3 III No NA No NA NA 3
PDTX-EMC003 Endometrioid Recurrence
(vagina)
3 NA D-Cis; H;
Ixa;C
no no NA N 24 3
PDTX-EMC056 Endometrioid with undifferentiated
component
Primary 3 I No NA No NA 6–12 4
PDTX-EMC042 Mixed Endometrioid/ Clear cell Primary 3 III No NA No NA NA 4
PDTX-EMC039 Mixed Endometrioid/ Clear cell Metastasis
(peritoneum)
3 IV No NA P-C Yes 12–24 4.5
PDTX-EMC035 Mixed Serous/ Clear cell Primary 3 III No NA T-C Yes 12–24 3
PDTX-EMC033 Serous Primary 3 I No NA No NA 12–24 7
PDTX-EMC051 Serous Primary 3 I No NA P-C NA 12–24 3
PDTX-EMC002 Serous Primary 3 III No NA No NA N24 5
PDTX-EMC008 Serous Primary 3 III No NA T-C Yes 12–24 5
PDTX-EMC053 Serous Primary 3 III No NA T-C Yes 12–24 2
PDTX-EMC047 Undiff. carcinoma Recurrence
(abdomen)
3 NA 5FU-Cis no No NA N24 2
PDTX-EMC022 Uterine mesonephric adenocarcinoma Primary 3 III No NA T-C; Cis Yes N24 5
PDTX-EMC007 Uterine mesonephric adenocarcinoma Recurrence
(vagina)
3 NA T-C yes T-C No N24 2
PDTX-EMC024 Uterine mesonephric adenocarcinoma Metastasis (pelvis) 3 NA No NA T-C; Cis Yes N24 8
NA: not applicable; Doc = Docetaxel; Cyclo = cyclophosphamide; T = Taxol; C = Carboplatinum; P = Paclitaxel; D = Doxorubicine; Cis = Cisplatinum; H = Hormone
(Aromasin); Ixa = Ixabepilone; 5FU = 5-Fluorouracil.
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classiﬁed in four different subtypes or clusters: POLE (ultramutated),
MSI (microsatellite-instable, hypermutated), copy-number low
(endometrioid) and copy-number high (serous-like) [3].
Such analyses also highlighted a high rate of PI3K/AKT pathway
mutations in ECs, compared to other tumor types, suggesting it as a
potential therapeutic target [4]. PI3K and/or mTOR inhibitors are
currently being evaluated in clinical trials, either as single agents or
in combination [5–8]. Nevertheless, ﬁrst reports suggest that, as
single agents, they are not as efﬁcacious as hoped [9]. One of the
reasons behind the failure of a large number of clinical trials for
novel targeted therapies is the lack of robust biomarkers for patient's
stratiﬁcation/inclusion. ECs are not an exception and most of the
already completed studies did not stratiﬁed patients based on the
molecular characterization of their tumors. An additional point to
consider is that the preclinical models conventionally used to test
novel therapies, although informative about the biology of the
tumor, are of poor clinical predictive value.
In the last decade there has been an increasing interest in the imple-
mentation of patient-derivedmodels as enhancedpreclinical tools. In par-
ticular, patient-derived tumor xenograft (PDTX) models, established by
implanting surgically removed tumor tissue in immunocompromised
mice, are expected to ﬁll the gap between preclinical and clinical research
[10]. PDTX models for several cancer types, including ovarian, breast, co-
lorectal and pancreatic cancer, have already been established and showed
their ability to reﬂect the histology and molecular features of the original
tumors and predict clinical outcomes in response to both chemo- and
targeted therapies [10–12].
Here, we present data about the establishment and molecular
characterization of a panel of ECs PDTX. Such a collection, comprising
all themain histologic andmolecular EC subtypes, represents a valuable
translational tool to study endometrial cancer cell biology and response
to therapy.
2. Materials and methods
2.1. Patient recruitment and sample collection
In collaborationwith the PDTX platform of the KU Leuven (Belgium),
PDTXmodels were established using primary or metastatic endometrial
carcinomas frompatients undergoing surgery in the University Hospitals
Fig. 1.Histologic overview of endometrial PDTXmodels. H&E stainingof 3 representativemodels of the different subtypes, an endometrioid, a serous and amesonefricmodel. Theﬁrst (F1)
and third (F3) generation xenograft tumors showed over time the same morphology as the primary tumor for all subtypes.
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Leuven, Academisch Ziekenhuis Groeninge Kortrijk and Université
Catholique de Louvain Saint-Luc Brussels. The study was approved by
the local ethical committees in accordance with the principles of the
Declaration of Helsinki and all patients gave their written informed
consent.
During surgery, fresh tumor tissue was collected in transport
medium, [RPMI 1640 medium supplemented with penicillin/strepto-
mycin (100 U/ml; 100 μg/ml), fungizone (1 μg/ml) and gentamicin
(50 μg/ml; all from Life Technologies)] and implanted in mice within
4 h. In parallel, primary tumor tissue fragments were also fresh-frozen
and formalin-ﬁxed for further analyses.
2.2. Establishment of patient-derived tumor xenografts
Before implantation, tumor tissue was rinsed in PBS (Life
Technologies) supplemented with penicillin/streptomycin and
fungizone, minced into pieces of 8–10 mm3 and implanted subcuta-
neously (s.c.) in both ﬂanks or in the interscapular region of
anesthetized 6-weeks-old female immunocompromised Nude mice
(Taconic, Denmark) (ﬁrst generation, F1). When the tumors reached
a tumor volume of 1500 mm3, mice were euthanized, tumors were
harvested and general necropsy was performed. Xenograft tumors
were immediately fresh-frozen, formalin-ﬁxed or placed in the
transport medium for serial transplantation into another set of im-
munocompromised mice (F2 generation). This process was repeated
to produce subsequent generations. The KU Leuven ethical commit-
tee approved all animal procedures.
2.3. Histological evaluation of patient-derived tumor xenografts
For all PDTX models, formalin-ﬁxed, parafﬁn-embedded (FFPE)
tissues sections from patient tumor samples and xenografts were
stained with hematoxylin and eosin (H&E). Immunohistochemical
stainings were performed on deparafﬁnized FFPE tissue sections
using antibodies against estrogen receptor (ER: 1/25; Dako), proges-
terone receptor (PGR: 1/40; Novocastra), human cytokeratin (CYT:
1/400; Dako), human-mouse vimentin (hu + mo-VIM; 1/1000;
Novus Biologicals), human vimentin (hu-VIM: 1/1000; Dako),
Mouse-α-Human MutS protein Homolog 1 (MLH1) (1/200; Dako),
Mouse-α-Human MutS protein Homolog 2 (MSH2: 1/50; Dako) or
Rabbit-α-Human MutS protein Homolog 6 (MHS2: 1/50; Dako). En-
dogenous peroxidase activity was quenched by incubation with 0.5%
hydrogen peroxide in methanol and washed in Tris-buffered saline
(TBS). For epitope retrieval, sections were exposed to citrate buffer
(pH 6.0) for 1 h at 80 °C (hu + mouse-VIM, hu-VIM), 1 h at 95 °C
(MSH6) or for 2 h at 90 °C (PGR). For MHL1 and MSH2 stainings, sec-
tions were incubated for 1 h in Tris–HCl buffer (pH 9.0) with 1 mM
EDTA at 95 °C and for ER staining incubation of 2 h in Tris–HCl buffer
(pH 9.0) with 1 mM EDTA at 90 °C was performed. For CYT staining,
sections were enzymatically treated with 0.04% pepsin in 0.01 N HCl
for 10 min at 37 °C. After blocking with 2% bovine serum albumin, 2%
milk powder and 0.01% Tween in TBS, sections were incubated with
the primary antibodies for 2 h (CYT) or overnight (ER, PGR, hu +
mouse-VIM, hu-VIM, MLH1, MSH2 and MSH6) in TBS, followed by
incubation with the corresponding secondary antibody labeled
with horseradish peroxidase for 30 min and antibody binding was
Fig. 2. Frequency ofMSI and POLEmutated tumors in endometrioid ECmodels. A) Status of different successfully engrafted endometrioid ECmodels. B) Frequency ofMSI (red),MSS (bleu)
and POLE-mutated (green) endometrioid ECmodels in engrafted and non-engrafted samples. Engraftedmodels had signiﬁcantly (p= 0.028) moreMSI and POLE-mutated samples com-
pared to non-engrafted models.
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visualized using 3,3-diaminobenzidine chromogen (DAB; Dako).
Sections were counterstained with Mayer's Hematoxylin.
2.4. Somatic single nucleotide variant detection by Whole Exome
Sequencing (WES)
DNA was extracted from primary tumor samples and the
corresponding xenograft (F3 generation) using DNeasy Blood and
Tissue Kit (Qiagen). Presence of tumor tissue was checked with H&E
slides. Micro-satellite instability (MSI) was checked as previously
described by Zhao et al. [13]. POLEmutationswere sequenced by Sanger
Sequencing of exons 9 and 13 [14].
Whole-exome sequencing was performed, as described previous-
ly [13,15]. DNA libraries for WES were prepared using the KAPA DNA
Library Preparation Kit (Illumina). After library preparation, exonic
fragments were captured with SeqCap EZ Human Exome Library
(Roche). These libraries were clustered on an Illumina V3 ﬂowcell
for subsequent 2 × 100 base pair pair-end sequencing on a
HiSeq2000 with an average coverage of 30× for germline, patient
tumor and xenograft samples. Raw sequencing reads were mapped
to the human reference genome (NCBI37/hg19) using Burrows-
Wheeler Aligner (BWA) and processed and sorted with SAM tools.
Duplicate reads were removed using Picard tools. Base recalibration,
local realignment around insertions and deletions and single nucleo-
tide variant calling were performed using the Genome Analysis Tool
Kit. To distinguish patient-speciﬁc mutations frommouse DNA in the
xenograft, all reads were mapped to both human (NCBI37/hg19) and
mouse (GRCm38/mm10) reference genome. Reads that mapped
unique to human genome were selected and used for further
analysis. Common variants (Major Allelic Frequency N1%) were
ﬁltered out using the following databases: dbSNP version 132, 1000
Genomes Project, Axiom Genotype Data Set and the Complete
Genomics diversity panel (46 Hapmap individuals). Exonic non-
synonymous mutations were selected for downstream analysis
with a coverage less than 5× in the germline DNA and higher then
10× in the primary tumor or xenograft. The cancer consensus
genes described by COSMIC [16] were used to compare between
the mutation proﬁles of primary and corresponding xenograft
tumors.
2.5. Copy number alteration detection by whole-genome low-coverage
(shallow) sequencing
DNA libraries for sequencing were prepared using KAPA DNA
Library Preparation Kit (Illumina). After library preparation, samples
were sequenced at low coverage on a HiSeq2000 (Illumina) using a
V3 ﬂowcell generating 1 × 50 bp reads. Raw sequencing reads were
mapped to the human reference genome (NCBI37/hg19) using
Burrows-Wheeler Aligner (BWA), revealing on average 12,124,835
mapped reads. Copy-number alterations were identiﬁed by
QDNAseq v. 1.0.5 [17] by binning the reads in 100 kb windows.
Bins in problematic regions were blacklisted, read counts were
corrected for GC-content and mappability using LOESS regression.
Read counts were normalized by the median and outliers were
smoothed. Segmentation of the bin values was performed by
ASCAT v. 2.0.7 [18]. When comparing the copy number alterations
between primary tumor and xenograft, each region with an absolute
difference in copy number of N0.5 was assumed to be different
between primary tumor and xenograft
2.6. Evaluation of the efﬁcacy of NVP-BEZ235 and AZD6244 in the
established PDX models
The efﬁcacy of treatment with NVP-BEZ235 (dual pan-PI3K/mTOR
inhibitor) and AZD6244 (MEK inhibitor) (Selleck Chemicals) on tumor
growth of mice bearing tumors with PTEN, PIK3CA and KRASmutations
(PDTX-EMC003 model) was evaluated. Tumor tissues of 9 mm3 were
s.c. implanted in the ﬂank of NRMI nude mice of 6 weeks old. Mice
were treated as previously described [19]. Brieﬂy, when tumors reached
a volume of ~150mm3micewere randomly distributed into ﬁve groups
(5 mice/group) and treated with either vehicle (10% NMP with 90%
PEG) (Sigma Aldrich), NVP-BEZ235 (40 mg/kg, daily, p.o.), AZD6244
(25 mg/kg, daily, p.o.), the combination of NVP-BEZ235 (40 mg/kg)
with AZD6244 (25 mg/kg) or carboplatin (50 mg/kg, 1×/week, i.p.).
For oral administration, NVP-BEZ235 and AZD6244 were dissolved
10% NMP with 90% PEG. Control animals received the equivalent
volume of vehicle (placebo group). All mice were treated for four
weeks. Mice were sacriﬁced 1 h after last treatment administration.
Xenografts were harvested, weighed and processed for further analyses
(fresh-frozen and formalin-ﬁxed).
All mice were weighed at regular intervals and screened for adverse
effects. Tumor size was measured 2×/week with a caliper and tumor
volume was calculated using the following formula: L × W2/2, with
L = tumor length; W= tumor width.
2.7. Western blotting
Total protein lysates were prepared from post-treatment fresh-
frozen tumor fragments using the mammalian cell lysis MCL1 kit
(Sigma Aldrich) according to the manufacturer's instructions. Total
protein concentration was determined with the Pierce BCA protein
assay kit (Thermo Scientiﬁc). An equal amount of proteins (30 μg) was
resolved in sodium dodecyl sulfate sample buffer, subjected to any kD
Mini Protein TGX gels (Bio-Rad) and transferred to a polyvinylidene
diﬂuoride membrane (Bio-Rad). Non-speciﬁc binding was blocked by
Fig. 3. Non-synonymous mutations in primary tumor and xenograft for PDTX-EMC003,
PDTX-EMC007, PDTX-EMC015 and PDTX-EMC053. Blue circles indicate mutations from
primary tumor, red indicate mutations from the xenograft. Common mutations between
primary tumor and xenograft are found in the center. Mutations found to be cancer
genes according to COSMIC are in green.
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incubation of the membrane in blocking buffer (5% non-fat dry milk
with 0.05% Tween in TBS). Next, membranes were incubated overnight
at 4 °C with the following primary antibodies (Cell Signaling
Technologies): AKT, p-AKT(Ser473), S6, p-S6(Ser235/Ser236), ERK1/2, p-
ERK1/2(Thr202/Tyr204) (all 1/1000), and beta-actin (1/2500) as a loading
control, after which membranes were incubated with rabbit or mouse
horseradish peroxidase-conjugated secondary antibodies (Bio-Rad).
All blots were developed by enhanced chemiluminescence and bands
were visualized using the FUJI mini-LAS 4000-plus imaging system
(GE Healthcare).
2.8. Statistics
One-way ANOVA for repeated measurements followed by a Tukey's
multiple comparison test was performed to assess differences in
therapy response over time between treatment groups. One-way
Fig. 4. Copy number alterations in PDTX-EMC003 obtained from whole genome low coverage sequencing. Centromeric regions are indicated as large red boxes below the ﬁgures. Acro-
centric chromosomes and heterechromatin (pericentric or telomeric) regions as small red boxes. Primary tumor and xenograft were compared by calculating the difference in copy num-
ber of each fragment between primary tumor and xenograft. Fragmentswith an absolute difference ofmore than 0.5 are indicated in red. Threshold values−0.5 and+0.5 indicated as red
dotted lines.
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ANOVA followed by Tukey'smultiple comparison test was performed to
assess differences in tumor weight between treatment groups. Statisti-
cal analyses were performed using Graphpad Prism 5 software. Results
are shown as mean ± standard error of mean (SEM). p b 0.05 was
considered as statistically signiﬁcant.
3. Results
3.1. Establishment of a panel of endometrial cancer patient-derived tumor
xenografts
We transplanted a total of 40 fresh primary, metastatic and/or
recurrent EC samples, obtained immediately after surgery, into im-
munocompromised mice and PDTXs were successfully engrafted
from 24 of them. Of these, 17 xenografts have been propagated
beyond an F3 generation, while 7 tumors are still growing in F2.
Among the 40 models, 16 models did not grow in F1. Taken together,
a success rate of 60% was reached when both F3 tumors and growing
tumors were considered as successfully engrafted. We validated
extensively 17 EC PDTX models, since of these tumors the F3 xeno-
grafts were available for histologic and genomic analysis. An over-
view of the successfully growing PDTX models and their clinical
characteristics of the original patients is represented in Table 1.
3.2. EC patient-derived tumor xenografts maintained the histologic
characteristics of the corresponding patient tumor
To histologically validate the established PDTX models, we
compared their general morphology, hormone receptor (ER, PGR)
status and CYT expression to the one of the corresponding primary
tumor. In all themodels, irrespectively of their histological classiﬁcation,
the tissue architecture and the epithelial compartment of the original
tumor, as shown by H&E and CYT staining, was preserved in the
corresponding F1 and F3 PDTXs (Fig. 1 and S1, respectively). In general,
we observed similarities in ER and PGR stainings between patient and
xenograft tumors (Fig. S1), although in general PGR expression seems
to be reduced in the xenografts.
3.3. In EC patient-derived tumor xenografts the human stromal component
is replaced by a reduced amount of murine stroma
To characterize the stroma in the PDTX tumors, we stained tumor
sections for vimentin, using two different antibodies: one speciﬁc for
human vimentin (hu-VIM) and a second one binding both human and
mouse vimentin (hu + mo-VIM). In all patient tumors, the stroma
stained positive for hu-VIM, but the staining was negative in the
PDTXs, indicating that the human-derived stroma was lost after tumor
Fig. 5.NVP-BEZ235 and AZD6244 reduce tumor growth in PDTXmodel harboring a PTEN, PIK3CA and KRASmutation. A) Tumor-bearing nudemicewere treated with either NVP-BEZ235
(40 mg/kg, daily, p.o.) or AZD6244 (25 mg/kg, daily, p.o.) or both (n = 5 mice/group) for four weeks. Single treatment of NVP-BEZ235 or AZD6244 showed tumor growth suppression.
Combination treatment showed stabilization of tumor growth. One-wayANOVA for repeatedmeasurements followedbya Tukey'smultiple comparison test. B)Wet tumorweight showed
a signiﬁcant difference in tumor weight compared to placebo group. One-way ANOVA followed by Tukey's multiple comparison test. C) Phosphorylation of AKT and S6 is reduced for tu-
mors of mice treated with NVP-BEZ235. In addition, AZD6244 induced reduction of p-ERK1/2 expression. Combination treatment showed reduction of phosphorylation of AKT, S6, and
ERK1/2. Results are shown as mean ± SEM. *p b 0.05, **p b 0.01, ***p b 0.001, compared with placebo group.
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engraftment inmice (Fig. S2). The human- andmouse-speciﬁc antibody
against vimentinwas strongly positive for xenograft stroma, conﬁrming
that, as already reported for other PDTXmodels [20], the human stroma
is replaced by a reduced amount of murine stroma after engraftment.
3.4. Engrafted endometrioid EC PDTX samples are enriched with MSI and
POLE mutated samples
MSI and POLEmutations are common in endometrioid ECs (33–40%
and 7% of the cases, respectively) and result in a higher mutation
frequency [3]. We checked all the engrafted and non-engrafted
endometrioid samples forMSI and POLEmutations (Fig. 2) and, compar-
ing them,we observed a signiﬁcant enrichment of MSI and POLEmutat-
ed tumors in the engrafted samples (Fisher's exact test; p= 0.028). The
MSI status was also conﬁrmed by immunohistochemical staining, since
MSI tumors are associated with a decreased expression of nuclear
MLH1, MSH2 or MSH6 [13]. All primary and correlated xenograft
tumors were positive for MSH2 and MHS6. In contrast, MSS tumors
expressed MLH1, whereas MSI tumors were negative for MLH1 (data
not shown).
3.5. Genetic analysis on patient-derived tumor xenograft showed high
similarity with patient tumors
Next, we performed WES on four models reﬂecting the different
more common and relevant subtypes in EC, i.e. two endometrioid, one
mesonephric and one serous EC. Among the endometrioid EC models,
we selected two models (grade 1 and grade 3, respectively) without
MSI or POLE mutations. We found an average of 57 (range 35–86)
non-silent mutations in the primary human tumors and 77 of them
(range 56–111) in the xenografts (Fig. 3). The majority of such
mutations were common between primary tumor and xenograft
(55%), while a minor fraction was unique either for the primary tumor
(11%) or for the xenograft (34%). Looking speciﬁcally at the cancer
consensus genes from COSMIC, we observed that most of themutations
were common between primary tumor and xenograft (Table S1). Next,
we validated mutations unique for primary tumor and xenograft with
ultra-deep targeted resequencing with a coverage N 500×. Among the
9 validatedmutations, 4were found to be false positives, 3were present
both in primary tumor and xenograft, while only 2 mutations arose
during engraftment (Table S2). The latter were both found in PDTX-
EMC0015, one mutation in THRAP3 was detected in a F3 generation
and one mutation in PDE4DIPwas detected in a F1 and F3 generation.
The copy number proﬁles generated using low-coverage whole-
genome sequencing for both the primary tumor and xenograft from
PDTX-EMC003 are shown in Fig. 4. Copy number proﬁles from the
other models are shown in Figs. S3–S5. On average, 90% (range 83%–
100%) of the genome had the same copy number between primary
tumor and xenograft. The regions with deletions or ampliﬁcations were
thus very well maintained during engraftment, even with the same
copy number and breakpoints for each region. Remarkably, this was
also observed in the serous subtype (PDTX-EMC053), while serous EC
are known to have a very high frequency of copy number alterations [3].
3.6. Endometrial patient-derived tumor xenograft model, with PTEN,
PIK3CA and KRAS mutations, is sensitive to combined PI3K/mTOR and
MEK inhibition
As a proof of concept, the efﬁcacy of PI3K/mTOR andMEK inhibitors
on in vivo tumor growth was evaluated in our PDTX-EMC003 PDTX
model, a high grade recurrent endometrioid carcinoma carrying PTEN,
PIK3CA and KRAS mutations (Table S1). To this purpose, NVP-BEZ235
(dual pan-PI3K/mTOR inhibitor) and AZD6244 (MEK1/2 inhibitor)
were selected. In this model, treatment with either NVP-BEZ235 or
AZD6244 signiﬁcantly slowed-down tumor growth as compared to
the placebo group. However, when treatment with NVP-BEZ235 and
AZD6244 was combined, tumor growth curve results in stable disease
(SD), as also observed for Carboplatin treatment (Fig. 5A), and
conﬁrmed by wet tumor weight analysis at sacriﬁce (Fig. 5B). In these
treated xenograft tumors, we also evaluated the phosphorylation levels
of the targeted molecules and observed that, as expected, NVP-BEZ235
reduced p-AKT and p-S6 expression. In AZD6244-treated tumors p-
ERK1/2 levels were markedly reduced. When both treatments were
combined, phosphorylation of AKT, S6 and ERK1/2 was reduced
(Fig. 5C), conﬁrming the on-target effect of the drugs.
4. Discussion
Patient derived tumor xenograft models have been established and
characterized for different types of cancers, including colorectal [21],
lung [22], pancreatic [23], breast [24] and ovarian carcinomas [11,12,
25]. Used as a complementary tool with the commercially available
immortalized cell lines, they showed high potential for preclinical
studies because of their ability to recapitulate the clinico-pathological
features of the human original tumors. Endometrial carcinomas are
the most frequent gynecological malignancies and treatment options
are still limited for advanced and recurrent diseases.
Here, we described the establishment of a panel of 24 PDTX
Endometrial Cancer models, comprising all the most relevant histologi-
cal subtypes. Importantly, the models closely resemble the histological
architecture of the original tumor tissues. As already shown for other
types of PDTX, once engrafted inmice, thehuman stromal compartment
of the tumors is replaced by a reduced amount of murine stroma.
Although this might represent a caveat for the use of the models for
testing stromal-directed therapies (such as antiangiogenic agents), it
has been recently showed that in colorectal cancer PDTX such phenom-
enon could be exploited to dissect the role of the epithelial and stromal
compartment in tumor development [26].
Notably, we demonstrated that PDTX models can be successfully
established from both type I and type II endometrial carcinomas, with
an overall engraftment rate of 60%. MSI and POLE mutations are a
phenomenon that occurs in about 33–40% and 7% of all endometrioid
EC, respectively [3]. Of the analyzed PDTX models, 62% were MSI and
15% POLE mutated. MSI and POLE mutated tumors can be resistant to
targeted therapies, because they acquire secondary mutations in genes
that activate alternative or downstream signaling pathways. We
observed a strong enrichment of MSI xenografts, suggesting a growth
advantage for such hypermutated tumors inmice, indicating the impor-
tance to test endometrioid EC PDTXmodels forMSI and POLEmutations,
especially when these models are used for the evaluation of targeted
therapies. To characterize at the molecular level the genomic landscape
of our PDTXs, we performed Whole Exome Sequencing and copy
number variation analyses on 4 models, representative of each relevant
EC subtypes: 1 low grade and 1 high grade endometrioid, 1 serous and 1
mesonephric. With regard to non-synonymous mutations, most
mutations were common between primary tumor and xenograft and a
small fraction of the mutations were unique for the primary tumor
and xenograft. Of note, we observed mutations in some of the most
frequently mutated genes in EC, such as PIK3CA, PTEN, ARID1A and
KRAS. Importantly, all but two mutations in cancer consensus genes
were retained between patient tumors and their corresponding
xenografts,meaningmost of the primary or xenograft uniquemutations
are just passengermutations. In addition, the copy number proﬁle of the
different models was very stable during engraftment, with an average
similarity of 90%.
Clinically relevant models, in addition to mirror the histological and
genomic features of the tumors in the patients, should also be of predic-
tive value about responses to standard and/or novel therapeutic regi-
mens. In particular, there is urgent need for preclinical models with
strong translational potential to test the efﬁcacy of targeted therapies
in EC patients with advanced, metastatic and recurrent diseases. PI3K/
AKT/PTEN/mTOR pathway is one of the most frequently dysregulated
125J. Depreeuw et al. / Gynecologic Oncology 139 (2015) 118–126
pathways in ECs and we characterized one of our PDTX models, PDTX-
EMC003 (recurrent endometrioid carcinoma carrying PTEN, PIK3CA
and KRASmutations, established from a patient at end-stage of disease),
for the response to NVP-BEZ235 (dual pan-PI3K/mTOR inhibitor),
AZD6244 (MEK1/2 inhibitor) and the combination of the two, since
PI3K/AKT/mTOR and Ras/Raf/MEK pathways can regulate each other
by cross-inhibition and cross-activation [27]. We observed that single
treatments with the targeted agents were able to just slow-down the
growth of the tumors, while the combination resulted in stable disease,
as also observed after Carboplatinum administration. Since protein
expression analyses showed the on-target effect of both drugs but
only stable diseasewas achieved, thismodelmight represent an optimal
candidate to study themolecular mechanisms engaged by the tumor to
resist to both chemo- and targeted therapies.
Here, we reported about the establishment of a panel of PDTX
models comprising the major histological and molecular subtypes of
endometrial cancer. Collectively, our data showed that such models
closely resemble the original human tumors in the patients in term of
tissue architecture and genomic features. A pilot treatment experiment
with targeted therapies against speciﬁc mutations in one of the model
also suggests that clinically annotated PDTXs might be of strong
potential for both fundamental and translational studies in ECs.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ygyno.2015.07.104.
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